Poorer survival outcomes in patients with multiple versus single primary melanoma.
immune profile
melanoma
multiple primary
survival
tumor-infiltrating lymphocytes
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
01 06 2022
01 06 2022
Historique:
revised:
02
02
2022
received:
18
10
2021
accepted:
14
02
2022
pubmed:
24
3
2022
medline:
11
5
2022
entrez:
23
3
2022
Statut:
ppublish
Résumé
Given equivocal results related to overall survival (OS) for patients with multiple primary melanomas (MPMs) compared with those with single primary melanomas (SPMs) in previous reports, the authors sought to determine whether OS differs between these 2 cohorts in their center using their UPCI-96-99 database. Secondary aims were to assess the differences in recurrence-free survival (RFS). In a subset of patients, transcriptomic profiling of peripheral blood mononuclear cells (PBMCs) was performed to assess disease-associated genes of interest. This retrospective case-controlled study included patients with MPMs and age-, sex-, and stage-matched controls with SPMs at a 1:1 ratio. Cox regression models were used to evaluate the effect of the presence of MPMs on death and recurrence. NanoString PanCancer Immune Profiling was used to assess peripheral blood immune status in patients. In total, 320 patients were evaluated. The mean patient age was 47 years; 43.8% were male. Patients with MPMs had worse RFS and OS (P = .023 and P = .0019, respectively). The presence of MPMs was associated with an increased risk of death (hazard ratio [HR], 4.52, P = .0006), and increased risk of disease recurrence (HR, 2.17; P = .004) after adjusting for age, sex, and stage. The degree of tumor-infiltrating lymphocytes (TILs) was different between the first melanoma of MPMs and SPMs. Expression of CXCL6 and FOXJ1 was increased in PBMCs isolated from patients with MPMs. Patients with MPMs had worse RFS and OS compared with patients with SPMs. Immunologic differences were also observed, including TIL content and expression of CXCL6/FOXJ1 in PBMCs of patients with MPMs, which warrant further investigation.
Sections du résumé
BACKGROUND
Given equivocal results related to overall survival (OS) for patients with multiple primary melanomas (MPMs) compared with those with single primary melanomas (SPMs) in previous reports, the authors sought to determine whether OS differs between these 2 cohorts in their center using their UPCI-96-99 database. Secondary aims were to assess the differences in recurrence-free survival (RFS). In a subset of patients, transcriptomic profiling of peripheral blood mononuclear cells (PBMCs) was performed to assess disease-associated genes of interest.
METHODS
This retrospective case-controlled study included patients with MPMs and age-, sex-, and stage-matched controls with SPMs at a 1:1 ratio. Cox regression models were used to evaluate the effect of the presence of MPMs on death and recurrence. NanoString PanCancer Immune Profiling was used to assess peripheral blood immune status in patients.
RESULTS
In total, 320 patients were evaluated. The mean patient age was 47 years; 43.8% were male. Patients with MPMs had worse RFS and OS (P = .023 and P = .0019, respectively). The presence of MPMs was associated with an increased risk of death (hazard ratio [HR], 4.52, P = .0006), and increased risk of disease recurrence (HR, 2.17; P = .004) after adjusting for age, sex, and stage. The degree of tumor-infiltrating lymphocytes (TILs) was different between the first melanoma of MPMs and SPMs. Expression of CXCL6 and FOXJ1 was increased in PBMCs isolated from patients with MPMs.
CONCLUSIONS
Patients with MPMs had worse RFS and OS compared with patients with SPMs. Immunologic differences were also observed, including TIL content and expression of CXCL6/FOXJ1 in PBMCs of patients with MPMs, which warrant further investigation.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
2098-2106Subventions
Organisme : NCI NIH HHS
ID : R01 CA204419
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA254865
Pays : United States
Informations de copyright
© 2022 American Cancer Society.
Références
Ferrone CR, Ben Porat L, Panageas KS, et al. Clinicopathological features of and risk factors for multiple primary melanomas. JAMA. 2005;294:1647-1654. doi:10.1001/jama.294.13.1647
Hwa C, Price LS, Belitskaya-Levy I, et al. Single versus multiple primary melanomas. Cancer. 2012;118:4184-4192. doi:10.1002/cncr.27407
Karapetyan L, Yang X, Wang H, et al. Indoor tanning exposure in association with multiple primary melanoma. Cancer. 2021;127:560-568. doi:10.1002/cncr.33307
Doubrovsky A, Menzies SW. Enhanced survival in patients with multiple primary melanoma. Arch Dermatol. 2003;139:1013-1018. doi:10.1001/archderm.139.8.1013
El Sharouni MA, Witkamp AJ, Sigurdsson V, van Diest PJ. Comparison of survival between patients with single vs multiple primary cutaneous melanomas. JAMA Dermatol. 2019;155:1049-1056. doi:10.1001/jamadermatol.2019.1134
Rowe CJ, Law MH, Palmer JM, MacGregor S, Hayward NK, Khosrotehrani K. Survival outcomes in patients with multiple primary melanomas. J Eur Acad Dermatol Venereol. 2015;29:2120-2127. doi:10.1111/jdv.13144
Kricker A, Armstrong BK, Goumas C, et al. Survival for patients with single and multiple primary melanomas: the genes, environment, and melanoma study. JAMA Dermatol. 2013;149:921-927. doi:10.1001/jamadermatol.2013.4581
Grossman D, Farnham JM, Hyngstrom J, et al. Similar survival of patients with multiple versus single primary melanomas based on Utah Surveillance, Epidemiology, and End Results data (1973-2011). J Am Acad Dermatol. 2018;79:238-244. doi:10.1016/j.jaad.2018.02.055
Karapetyan L, Kirkwood JM. State of melanoma: an historic overview of a field in transition. Hematol Oncol Clin North Am. 2021;35:1-27. doi:10.1016/j.hoc.2020.09.003
Twine NC, Stover JA, Marshall B, et al. Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma. Cancer Res. 2003;63:6069-6075.
Chang DH, Rutledge JR, Patel AA, Heerdt BG, Augenlicht LH, Korst RJ. The effect of lung cancer on cytokine expression in peripheral blood mononuclear cells. PLoS One. 2013;8:e64456. doi:10.1371/journal.pone.0064456
Baine MJ, Chakraborty S, Smith LM, et al. Transcriptional profiling of peripheral blood mononuclear cells in pancreatic cancer patients identifies novel genes with potential diagnostic utility. PLoS One. 2011;6:e17014. doi:10.1371/journal.pone.0017014
Hotson D, Alvarado R, Conroy A, et al. Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for clinical response biomarker identification. J Immunother Cancer. 2013;1:P257. doi:10.1186/2051-1426-1-S1-P257
Helgadottir H, Isaksson K, Fritz I, et al. Multiple primary melanoma incidence trends over five decades: a nationwide population-based study. J Natl Cancer Inst. 2021;113:318-328. doi:10.1093/jnci/djaa088
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7-33. doi:10.3322/caac.21654
Welch HG, Mazer BL, Adamson AS. The rapid rise in cutaneous melanoma diagnoses. N Engl J Med. 2021;384:72-79. doi:10.1056/NEJM.sb2019760
Saleh FH, Crotty KA, Hersey P, Menzies SW. Primary melanoma tumour regression associated with an immune response to the tumour-associated antigen melan-A/MART-1. Int J Cancer. 2001;94:551-557. doi:10.1002/ijc.1491
Youlden DR, Baade PD, Soyer HP, et al. Ten-year survival after multiple invasive melanomas is worse than after a single melanoma: a population-based study. J Invest Dermatol. 2016;136:2270-2276. doi:10.1016/j.jid.2016.03.014
Pardo LM, van der Leest RJ, de Vries E, Soerjomataram I, Nijsten T, Hollestein LM. Comparing survival of patients with single or multiple primary melanoma in the Netherlands: 1994-2009. Br J Dermatol. 2017;176:531-533. doi:10.1111/bjd.14846
Menzies S, Barry R, Ormond P. Multiple primary melanoma: a single centre retrospective review. Melanoma Res. 2017;27:638-640. doi:10.1097/cmr.0000000000000395
Van Damme JO, Wuyts A, Froyen G, et al. Granulocyte chemotactic protein-2 and related CXC chemokines: from gene regulation to receptor usage. J Leukoc Biol. 1997;62:563-569. doi:10.1002/jlb.62.5.563
Zhu YM, Bagstaff SM, Woll PJ. Production and upregulation of granulocyte chemotactic protein-2/CXCL6 by IL-1β and hypoxia in small cell lung cancer. Br J Cancer. 2006;94:1936-1941. doi:10.1038/sj.bjc.6603177
Verbeke H, Struyf S, Berghmans N, et al. Isotypic neutralizing antibodies against mouse GCP-2/CXCL6 inhibit melanoma growth and metastasis. Cancer Lett. 2011;302:54-62. doi:10.1016/j.canlet.2010.12.013
Van Coillie E, Van Aelst I, Wuyts A, et al. Tumor angiogenesis induced by granulocyte chemotactic protein-2 as a countercurrent principle. Am J Pathol. 2001;159:1405-1414. doi:10.1016/s0002-9440(10)62527-8
Lin L, Spoor MS, Gerth AJ, Brody SL, Peng SL. Modulation of Th1 activation and inflammation by the NF-κB repressor Foxj1. Science. 2004;303:1017-1020. doi:10.1126/science.1093889
Lin L, Brody SL, Peng SL. Restraint of B cell activation by Foxj1-mediated antagonism of NF-κB and IL-6. J Immunol. 2005;175:951-958. doi:10.4049/jimmunol.175.2.951
Lan Y, Hu X, Jiang K, Yuan W, Zheng F, Chen H. Significance of the detection of TIM-3 and FOXJ1 in prostate cancer. J Buon. 2017;22:1017-1021.
Xian S, Shang D, Kong G, Tian Y. FOXJ1 promotes bladder cancer cell growth and regulates Warburg effect. Biochem Biophys Res Commun. 2018;495:988-994. doi:10.1016/j.bbrc.2017.11.063
Zhu P, Piao Y, Dong X, Jin Z. Forkhead box J1 expression is upregulated and correlated with prognosis in patients with clear cell renal cell carcinoma. Oncol Lett. 2015;10:1487-1494. doi:10.3892/ol.2015.3376